CTLA4 and non-small cell lung carcinoma: Targeting co-inhibitory receptors or immune checkpoints such as PD-1 and CTLA-4 by antibody blockade, alone or in combination, is now an established strategy for treating patients with melanoma and non-small cell lung cancer [57–59].